TAB1 (N-terminus) monoclonal Antibody | MB0107

TAB1 (N-terminus) monoclonal Antibody | MB0107 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Application: WB

Application Range: WB: 1:1000

Background: The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: This Antibody detects endogenous levels of TAB1 and does not cross-react with related proteins

Molecular Weight: Predicted band size:55KDa Observed band size:55KDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; Mitogen-activated protein kinase kinase kinase 7-interacting protein 1; TGF-beta-activated kinase 1-binding protein 1; TAK1-binding protein 1; TAB1; MAP3K7IP1

Immunogen: Synthetic peptide, corresponding to the N-terminus of Human TAB1.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from mouse ascites by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: